Evidence map›Paper›PMID 40867802›Full record

ArticleAntioxidants (Basel, Switzerland)2025

An Immune Assay to Quantify the Neutralization of Oxidation-Specific Epitopes by Human Blood Plasma.

Marija Jelic, Philipp Jokesch, Olga Oskolkova, Gernot Faustmann, Brigitte M Winklhofer-Roob, Bernd Ullrich, Jürgen Krauss, Rudolf Übelhart, Bernd Gesslbauer, Valery Bochkov

Abstract read
In one paragraph

Article in Antioxidants (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Marija JelicDepartment of Pharmaceutical Chemistry, Institute of Pharmaceutical Sciences, University of Graz, 8010 Graz, Austria.
Philipp JokeschDepartment of Pharmaceutical Chemistry, Institute of Pharmaceutical Sciences, University of Graz, 8010 Graz, Austria.ORCID 0009-0002-7768-0641
Olga OskolkovaDepartment of Pharmaceutical Chemistry, Institute of Pharmaceutical Sciences, University of Graz, 8010 Graz, Austria.ORCID 0000-0001-9443-8705
Gernot FaustmannInstitute of Molecular Biosciences, University of Graz, 8010 Graz, Austria.ORCID 0000-0003-2184-0175
Brigitte M Winklhofer-RoobInstitute of Molecular Biosciences, University of Graz, 8010 Graz, Austria.
Bernd UllrichHeidelberg ImmunoTherapeutics GmbH, 69115 Heidelberg, Germany.
Jürgen KraussVanudis GmbH, 69115 Heidelberg, Germany.
Rudolf ÜbelhartVanudis GmbH, 69115 Heidelberg, Germany.
Bernd GesslbauerDepartment of Pharmaceutical Chemistry, Institute of Pharmaceutical Sciences, University of Graz, 8010 Graz, Austria.ORCID 0000-0003-4910-8322
Valery BochkovDepartment of Pharmaceutical Chemistry, Institute of Pharmaceutical Sciences, University of Graz, 8010 Graz, Austria.ORCID 0000-0003-3043-1736

Funding

Austrian Science Fund 10.55776/P35129European Union Framework Programme 7 FP7 2007-2013 244995
6 · The paper itself

Abstract

Oxidized phospholipids (OxPLs) are increasingly recognized as biologically active lipids involved in various pathologies. Both exposure to pathogenic factors and the efficacy of protective mechanisms are critical to disease development. In this study, we characterized an immunoassay that quantified the total capacity of the plasma to degrade or mask OxPLs, thereby preventing their interaction with cells and soluble proteins. OxLDL-coated plates were first incubated with human blood plasma or a control vehicle, followed by an ELISA using a monoclonal antibody specific to oxidized phosphatidylethanolamine. Pretreatment with the diluted blood plasma markedly inhibited mAb binding. The masking assay was optimized by evaluating the buffer composition, the compatibility with various anticoagulants, potential interfering compounds, the kinetic parameters, pre-analytical stability, statistical robustness, and intra- and inter-individual variability. We propose that this masking assay provides a simple immunological approach to assessing protective mechanisms against lipid peroxidation products. Establishing this robust and reproducible method is essential for conducting clinical association studies that explore masking activity as a potential biomarker of the predisposition to a broad range of lipid-peroxidation-related diseases.

Indexed as

ELISAoxidation-specific epitopesoxidized phospholipidsOxLDL

Identifiers

PMID40867802
PMCPMC12383025

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.